2,521.74 18.01 (+0.72%)

    901.23 9.62 (+1.08%)
  • Dollar/Won

    1,062.70 0.00 (0.00%)
증권시황 정보 열기

Samsung’s anti-cancer biosimilar Samfenet approved in Korea

2017.11.09 14:22:49 | 2017.11.09 14:23:29
  • print
  • email
  • facebook
  • twitter
  • share
이미지 확대
Samsung Bioepis Co., a joint venture between South Korea’s Samsung BioLogics Co. and U.S.-based Biogen Inc., has received marketing approval of Samfenet, a trastuzumab biosimilar, from Korean health authorities, Samsung BioLogics said in a regulatory filing on Thursday.

The biosimilar, SB3, referenced on Roche`s Herceptin, is Samsung’s first approved oncology drug and is indicated for the treatment of patients with primary and metastatic breast and gastric cancer.

Herceptin generated global sales of nearly $7 billion in 2016 for the Swiss pharmaceutical giant. It was the eighth best-selling drug in the world.

A Samsung Bioepis official said "Samfenet will be launched in Korea after its local distributor is determined with a drug price.

In September, Samsung Bioepis received a positive opinion from the EMA`s Committee for Medicinal Products for Human Use on approval of Samfenet under a brand name of Ontruzant in Europe. The company expects it to be approved as early as this month.

By Kim Hye-soon and Minu Kim

[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]



  • Seoul Tue 16 January 2018
  • TUE


Get Newsletters